Table 1.
Adherence in Wearing Activity Tracker among African American Breast Cancer Survivors in eHealth Weight Loss Trial.
| Baseline characteristics | Na | Months 1–3 days/week Median (IQR) | p-valueb | Months 4–6 days/week Median (IQR) | p-valueb | Na,c | Months 7–9 days/week Median (IQR) | p-valueb | Months l0-l2 days/week Median (IQR) | p-valueb |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Overall | 44c | 6.73 (1.09) | 6.35 (1.73) | 34 | 6.42 (l.8l) | 6.23 (l.40) | ||||
| Intervention group | 0.738 | 0.868 | 0.73 | 0.65 | ||||||
| Fitbit onlyd | 17 | 6.85 (1.50) | 6.00 (1.61) | l7 | 6.62 (2.23) | 6.23 (l.27) | ||||
| SparkPeople + Fitbit | 17 | 6.69 (1.23) | 6.54 (l.88) | l7 | 6.38 (l.54) | 6.l5 (2.77) | ||||
| SparkPeople Premium + Fitbit | 10 | 6.81 (0.44) | 6.39 (2.46) | 0 | — | — | ||||
| Age | 0.693 | 0.439 | 0.l2 | 0.044 | ||||||
| < 60 years | 19 | 6.69 (1.85) | 6.08 (2.00) | l4 | 5.88 (2.46) | 5.69 (2.98) | ||||
| ≥ 60 years | 25 | 6.85 (0.73) | 6.62 (l.65) | 20 | 6.65 (0.85) | 6.46 (0.92) | ||||
| Marital Status | 0.645 | 0.857 | 0.826 | 0.9l6 | ||||||
| Married | 17 | 6.77 (0.92) | 6.54 (2.16) | l3 | 6.38 (l.08) | 6.23 (3.23) | ||||
| Widowed/divorced | 12 | 6.47 (1.59) | 6.00 (1.76) | l2 | 6.00 (2.83) | 5.85 (l.62) | ||||
| Never married/unknown | 14 | 6.77 (0.69) | 6.62 (l.l3) | 8 | 6.65 (l.40) | 6.3l (3.38) | ||||
| Employment status | 0.859 | 0.78l | 0.4l3 | 0.305 | ||||||
| Employed | 17 | 6.85 (0.80) | 6.62 (l.6l) | l0 | 6.35 (l.46) | 5.96 (0.87) | ||||
| Unemployed | 7 | 6.77 (1.92) | 6.08 (2.85) | 7 | 5.77 (2.77) | 4.85 (3.60) | ||||
| Retired | 20 | 6.69 (1.30) | 6.3l (2.27) | l7 | 6.46 (2.l5) | 6.46 (l.00) | ||||
| Education | 0.051 | 0.799 | 0.874 | 0.654 | ||||||
| High school or less | 6 | 6.27 (3.56) | 6.08 (4.60) | 5 | 6.69 (3.69) | 6.27 (4.46) | ||||
| Some college | 15 | 7.00 (0.38) | 5.08 (l.46) | ll | 6.38 (2.46) | 5.85 (2.3l) | ||||
| College graduate | 23 | 6.69 (1.15) | 6.62 (l.69) | l8 | 6.42 (l.l0) | 6.62 (l.35) | ||||
| Number of people in household | 0.161 | 0.l25 | 0.008 | 0.0l2 | ||||||
| 1 | 10 | 6.77 (1.15) | 6.35 (l.77) | 7 | 4.92 (2.69) | 5.69 (3.00) | ||||
| 2–3 | 25 | 6.85 (0.54) | 6.62 (l.l5) | 20 | 6.69 (0.69) | 6.62 (0.85) | ||||
| 4–5 | 9 | 4.69 (3.62) | 3.77 (4.66) | 7 | 3.46 (4.85) | 3.69 (4.54) | ||||
| Number of conditions | 0.039 | 0.062 | 0.l4 | 0.205 | ||||||
| 0–2 | 20 | 6.92 (0.44) | 6.66 (l.29) | l2 | 6.42 (0.7l) | 6.27 (l.l0) | ||||
| 3–4 | 14 | 6.73 (0.98) | 6.08 (l.62) | l2 | 6.77 (l.l0) | 6.3l (l.2l) | ||||
| ≥5 | 10 | 5.10 (3.42) | 4.66 (4.48) | l0 | 4.69 (4.l5) | 4.46 (4.90) | ||||
| Charlson comorbidity | 0.641 | 0.27 | 0.7l4 | 0.9l3 | ||||||
| 0 | 23 | 6.85 (0.69) | 6.62 (l.54) | l6 | 6.54 (l.l7) | 6.l5 (l.l0) | ||||
| 1 | 13 | 6.69 (1.54) | 6.00 (l.88) | l0 | 6.l9 (l.98) | 6.23 (3.96) | ||||
| ≥2 | 8 | 6.73 (3.04) | 5.35 (4.50) | 8 | 6.l9 (3.8l) | 6.23 (3.77) | ||||
| Breast cancer stage | 0.259 | 0.637 | 0.034 | 0.08 | ||||||
| 0 or I | 16 | 6.85 (0.83) | 6.39 (l.3l) | l3 | 6.77 (0.73) | 6.62 (0.65) | ||||
| II | 15 | 6.62 (2.3l) | 6.08 (4.39) | l0 | 5.27 (3.l7) | 5.69 (2.88) | ||||
| III | 7 | 7.00 (0.46) | 6.54 (1.3l) | 7 | 6.38 (l.08) | 5.92 (l.l7) | ||||
| Chemotherapy | 0.416 | 0.75 | 0.86l | 0.803 | ||||||
| No | 16 | 6.54 (1.32) | 6.70 (l.93) | l3 | 6.46 (2.62) | 6.35 (3.l2) | ||||
| Yes | 28 | 6.77 (0.42) | 6.l2 (l.79) | 2l | 6.38 (l.42) | 6.l5 (0.98) | ||||
| Years since diagnosis | 0.29 | 0.93l | 0.558 | 0.053 | ||||||
| 1–5 | 20 | 6.92 (0.56) | 6.08 (l.52) | l5 | 6.38 (l.38) | 6.65 (l.56) | ||||
| ≥ 6 | 14 | 6.66 (0.7l) | 6.08 (l.99) | 9 | 6.23 (2.l2) | 5.85 (0.69) | ||||
| Baseline BMI (kg/m2) | 0.239 | 0.473 | 0.304 | 0.245 | ||||||
| 25–29.9 | 7 | 6.69 (1.30) | 6.00 (l.62) | 6 | 6.l9 (l.58) | 6.46 (2.l3) | ||||
| 30–34.9 | 17 | 6.69 (1.00) | 6.00 (2.23) | ll | 6.23 (l.38) | 6.l5 (l.96) | ||||
| 35–39.9 | 7 | 6.92 (0.15) | 6.77 (0.30) | 7 | 6.77 (0.23) | 6.3l (0.85) | ||||
| 40+ | 11 | 6.62 (3.23) | 6.62 (4.77) | l0 | 5.50 (3.62) | 5.69 (4.58) | ||||
| Smoking status | 0.524 | 0.056 | 0.074 | 0.254 | ||||||
| never | 31 | 6.77 (1.00) | 6.69 (l.6l) | 22 | 6.54 (0.69) | 6.23 (l.08) | ||||
| current or former | 13 | 6.69 (2.54) | 6.00 (2.85) | l2 | 5.62 (3.08) | 5.69 (3.46) | ||||
| Baseline QOL category | 0.469 | 0.11 | 0.418 | 0.788 | ||||||
| 1 (best) | 12 | 6.92 (0.83) | 6.81 (0.32) | 10 | 6.77 (1.21) | 6.27 (1.31) | ||||
| 2 | 11 | 6.69 (1.38) | 5.92 (l.3l) | 8 | 5.88 (2.13) | 6.69 (1.08) | ||||
| 3 | 12 | 6.62 (2.17) | 5.54 (4.22) | 8 | 5.65 (4.69) | 5.69 (5.38) | ||||
| 4 (worst) | 9 | 6.69 (0.81) | 6.62 (0.81) | 8 | 6.46 (0.48) | 6.15 (2.69) | ||||
| Fatigue in past 4 weeks | 0.437 | 0.111 | 0.251 | 0.737 | ||||||
| Never—sometimes | 25 | 6.85 (0.77) | 6.62 (1.46) | 18 | 6.50 (0.90) | 6.23 (1.00) | ||||
| More often—always | 19 | 6.69 (1.92) | 6.08 (3.00) | 16 | 6.35 (3.54) | 5.85 (3.69) | ||||
| Poor physical health in past | 0.246 | 0.339 | 0.585 | 0.427 | ||||||
| 30 days | ||||||||||
| 0 | 22 | 6.88 (0.71) | 6.12 (2.23) | 14 | 6.31 (2.23) | 6.62 (1.38) | ||||
| 1–5 | 13 | 6.85 (0.54) | 6.62 (0.77) | 12 | 6.54 (0.71) | 6.23 (0.96) | ||||
| > 5 | 9 | 5.77 (2.66) | 6.00 (5.12) | 8 | 5.77 (4.06) | 5.85 (4.77) | ||||
| Poor mental health in past | 0.605 | 0.15 | 0.585 | 0.89 | ||||||
| 30 days | ||||||||||
| 0 | 17 | 6.85 (0.65) | 6.77 (1.38) | 12 | 6.69 (1.71) | 6.23 (1.00) | ||||
| 1–5 | 11 | 6.92 (1.38) | 6.54 (1.31) | 8 | 6.38 (0.81) | 6.15 (1.02) | ||||
| > 5 | 13 | 6.62 (l.54) | 6.00 (3.31) | 12 | 6.35 (2.48) | 6.23 (3.62) | ||||
Abbreviation: IQR Interquartile range.
a
Numbers may not add to total due to missing data.
b
p-value using non-parametric Mann-Whitney U-Test or Kruskal-Wallis Test.
c
N = 34 for Months 7–12 data (Spark Premium + Fitbit group was only in study for 6 months).
d
Fitbit only group started SparkPeople in Month 7.